GENESCO INC
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Net sales | $2.44B+4.8% | $2.33B+0.0% | $2.32B-2.5% | $2.38B-1.5% | $2.42B |
| Cost of sales | $1.31B+6.6% | $1.23B+0.2% | $1.23B-1.8% | $1.25B+0.6% | $1.24B |
| Gross margin | $1.13B+2.7% | $1.10B-0.2% | $1.10B-3.3% | $1.14B-3.8% | $1.18B |
| Selling and administrative expenses | $1.10B+2.0% | $1.08B-0.2% | $1.08B+3.8% | $1.04B+0.8% | $1.03B |
| Goodwill impairment | $0 | $0-100.0% | $28.5M | $0 | $0 |
| Asset impairments and other, net | $8.1M+149.4% | $3.2M+81.0% | $1.8M+109.0% | $855K+110.6% | -$8.1M |
| Operating income (loss) | $17.3M+24.3% | $13.9M+203.5% | -$13.5M-114.4% | $93.2M-40.1% | $155.6M |
| Other components of net periodic benefit cost | $625K+70.3% | $367K-31.7% | $537K+116.5% | $248K+93.8% | $128K |
| Interest expense (net of interest income of $0.7 million, $0.7 million and $0.4 million for Fiscal 2026, 2025 and 2024, respectively) | $4.1M-3.6% | $4.3M-45.4% | $7.8M+166.3% | $2.9M+19.3% | $2.4M |
| Earnings (loss) from continuing operations before income taxes | $12.6M+35.3% | $9.3M+142.7% | -$21.8M-124.2% | $90.1M-41.1% | $153.0M |
| Income tax expense (benefit) | -$685K-102.4% | $28.8M+1454.5% | $1.9M-89.6% | $17.8M-53.1% | $38.0M |
| Earnings (loss) from continuing operations | $13.3M+168.0% | -$19.5M+17.4% | -$23.6M-132.7% | $72.2M-37.2% | $114.9M |
| Gain (loss) from discontinued operations, net of tax | -$7K-101.1% | $622K-90.9% | $6.8M+2179.8% | -$327K-237.1% | -$97K |
| Net Earnings (Loss) | $13.3M+170.2% | -$18.9M-12.3% | -$16.8M-123.4% | $71.9M-37.4% | $114.8M |
| Continuing operations (in dollars per share) | $1250.00+169.4% | -$1800.00+14.3% | -$2100.00-136.9% | $5690.00-28.2% | $7920.00 |
| Discontinued operations (in dollars per share) | $0.00-100.0% | $60.00-90.0% | $600.00+2100.0% | -$30.00 | $0.00 |
| Net earnings (loss) (in dollars per share) | $1250.00+171.8% | -$1740.00-16.0% | -$1500.00-126.5% | $5660.00-28.5% | $7920.00 |
| Basic (in shares) | 10.4M-4.3% | 10.8M-3.6% | 11.2M-9.7% | 12.5M-12.1% | 14.2M |
| Diluted (in shares) | 10.6M-2.0% | 10.8M-3.6% | 11.2M-11.5% | 12.7M-12.4% | 14.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Genesco beat Q1 FY2027 expectations with comparable sales growth of 2% and raised full-year EPS guidance to $2.00-$2.40
“After a strong finish to Fiscal 2026, we are pleased to report a solid start to Fiscal 2027, delivering our seventh consecutive quarter of positive comparable sales and first quarter results that exceeded expectations across the board.”
No Form 4 transactions on record.
Informational purposes only, not investment advice.